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A study published by Hanrath and colleagues 1 in this Jour- 
al found no SARS-CoV-2 reinfection cases between the first two 
aves of the pandemic in a cohort of healthcare workers. How- 
ver, several SARS-CoV-2 reinfection cases have been reported dur- 
ng the second wave, although reinfection definitions are not con- 
istent. 2 , 3 
It is crucial to understand whether SARS-CoV-2 antibody titres 
ould be used as a correlate of protection in assessment of disease 
usceptibility. In the SIREN study, a large national longitudinal co- 
ort of more than 44,0 0 0 healthcare workers, participants are fol- 
owed for at least 12 months using fortnightly symptom and expo- 
ure questionnaires and nucleic acid amplification testing (NAAT), 
ith monthly antibody testing against SARS-CoV-2. 4 Potential re- 
nfections are flagged when meeting the following criteria: two 
ositive RT-PCR tests at least 90 days apart (with no additional 
ntervening positives) or a new RT-PCR positive test at least four 
eeks after a positive SARS-CoV-2 antibody test. Additional total 
ntibody testing is performed at Public Health England laboratory 
sing the semi-quantitative Elecsys Anti-SARS-CoV-2 nucleocapsid 
N) protein assay and fully quantitative Elecsys Anti-SARS-CoV-2 
pike (S) protein assay which targets the receptor binding domain 
RBD) (Roche Diagnostics). 5 
We here describe two reinfection cases in which additional 
erological assays were performed: in-house recombinant SARS- 
oV-2 IgG spike (S) protein RBD indirect ELISA, 6 live virus 
icroneutralisation using SARS-CoV-2 isolate England/02/2020. 7 
nd pseudovirus neutralisation. 8 Semi-automated multiplexed 
mmuno-blotting assay was performed to detect RBD-, N-, S1-, S2- 
nd S-specific IgG, IgA and IgM antibodies. 8 
ase 1 
A 45-year-old female nurse, with history of asthma and treated 
reast cancer, was SARS-CoV-2 antibody positive on 7th August 
020. She reported COVID-19 symptoms in March 2020 (dry cough, 
ever, headache and myalgia, followed by anosmia and ageusia), 
owever RT-PCR was not performed. On 10th October, during a 
osocomial outbreak of SARS-CoV-2, she became SARS-CoV-2 PCR 
ositive, however asymptomatic at the time of testing. Four days 
ater, she reported headache followed by sore throat, myalgia, 
rthralgia, ageusia and a productive cough. She reported milder 
ymptoms during the second episode. 
SARS-CoV-2 was successfully cultured from the earliest of sev- 
ral samples taken between 10th to 23rd October. A phylogenetic 
nalysis was undertaken to compare sequences derived from the 
CR positive swabs with circulating SARS-CoV-2 strains in the UK, 
sing cluster investigation and viral epidemiology tools (Pangolin ttps://doi.org/10.1016/j.jinf.2021.09.019 
163-4453/© 2021 Published by Elsevier Ltd on behalf of The British Infection AssociationOVID-19 Lineage Assigner). Infection was due to SARS-CoV-2 lin- 
age B.1.523 with exact concordance between all sequences ob- 
ained from the individual. Sequences segregated to the same lin- 
age, within one or two SNPs as samples from 18 other individuals 
nvolved in the nosocomial outbreak. 
Prior to reinfection, S binding antibodies (RBD ELISA and Roche 
/RBD ECLIA) and neutralising antibodies (live virus and pseu- 
ovirus) were at or below the limit of detection but were boosted 
ignificantly following reinfection, with neutralising antibodies in- 
reased to high titres > 1:10 0 0 33 days after reinfection ( Fig. 1 ). 
The immuno-blotting results ( Fig. 2 a) demonstrated N-specific 
gG was clearly detectable at the time of reinfection, whereas the 
ntensity of the S-specific band was weak, consistent with other 
erological results. IgM levels were undetectable. In contrast, all 
ntigens except S2 were clearly detectable by IgA 30 days after re- 
nfection. 
ase 2 
A 37-year-old female administrator had SARS-CoV-2 antibodies 
n 28th August 2020. She described COVID-19 symptoms in March 
020, (fever, shortness of breath, flu-like symptoms, anosmia and 
geusia) that lasted 4 weeks, when no RT-PCR test was performed. 
 surveillance RT-PCR test undertaken on 06th October 2020 was 
ositive, when she had coryzal symptoms and diarrhoea that lasted 
ess than 24 h, with no other symptoms. 
Genomic analysis identified from swabs on 6th and 9th October 
ere identical and belonging to B.1.258.4 lineage. Serology demon- 
trated an increase in antibody reactivity in all assays following the 
econd infection ( Fig. 1 ). Prior to the reinfection, both N and S an-
ibodies were detectable with low levels of neutralising antibodies 
live virus and pseudovirus). However, within three days of rein- 
ection, neutralising antibodies increased to a titre of > 1:200. 
Previous exposure to SARS-CoV-2 was evident from the 
mmuno-blot ( Fig. 2 b). Thus, IgG and IgA specific to the Nucleo- 
apsid protein, but not other antigens, could be detected prior to 
he onset of symptoms. Two weeks later, an increase in antibody 
esponses was observed, against the N antigen, Spike antigen, RBD 
nd S1 sub-domains. IgM was detected against N and S1, albeit 
eaker against the latter antigen. 
The mechanisms of failure of immune protection from rein- 
ection have not been clearly elucidated. In these two cases, an 
namnestic antibody response was observed using virus neutrali- 
ation, antibody binding and immuno-blotting assays. All investi- 
ations showed an increase in antibody levels following the onset 
f symptoms in both cases and low or absent levels of neutralising 
ntibodies at time of reinfection. This might be due to a lack of 
ffective antibody response after the first infection or decrease in 
eutralising antibody titres over time, as observed in other stud- 
es. 9 . 
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Fig. 1. Serological response in Case 1 and Case 2 against SARS-CoV-2, including anti-N, anti-S, anti-RDB and neutralising antibodies. Vertical dashlines represent the re- 
infection events for Case 1 (red) and Case 2 (blue). Horizontal dashline represents cutoff values. (a) Anti-SARS-CoV-2 nucleocapsid (N) protein assay (Roche Diagnostics - 
Cutoff ≥ 1.0 U/mL). (b) Fully quantitative Elecsys Anti-SARS-CoV-2 spike (S) protein assay (Roche Diagnostics - Cutoff ≥ 0.8 U/mL). 5 (c) In-house recombinant SARS-CoV-2 
IgG spike (S) protein receptor binding domain (RBD) indirect ELISA (Cutoff ≥ 5.0). 6 (d) Neutralising antibodies were detected using a live virus microneutralisation assay, 
using England/2/2020 virus (Cutoff ≥ 20.0). 7 
Fig. 2. Immuno-blotting of Case 1 (a) and Case 2 (b) plasma samples showing the reactivity of IgG (left), IgA (middle) and IgM (right) against the Spike, S1, S2, N and RBD 

























Our data are consistent with the hypothesis that absence or low 
evels of neutralising antibody titres are likely correlate with a lack 
f protection against SARS-CoV-2 reinfection. There is strong ev- 
dence that neutralising antibodies play a critical protective role. 
as estimated that neutralising antibody titres can offer an ac- 
urate prediction of immune protection, with neutralisation level 
or 50% protection being 54 U/mL, which equates to a titre of 1:10 
r 1:30 in most virus neutralisation assays. 10 The sera from both 
ases had virus neutralising antibody levels below this threshold 
t the time of SARS-CoV-2 reinfection. 
There are some limitations in this study: no samples from the 
rst infection episodes were available, thus no comparative ge- 
omic analysis of infecting viruses was possible. However, the se- 
uences obtained in October were genetically distant from SARS- 
oV-2 viruses from March 2020 but closely related to viruses cir- 
ulating locally at time of reinfection. Secondly, symptoms from 2 he first infection episodes are subject to recall bias. Finally, our 
nalysis was restricted to two cases; therefore, our hypothesis will 
equire support from more extensive studies. Further analysis us- 
ng a case-control design is essential to clarify the potential role of 
eutralising antibodies in SARS-CoV-2 reinfection. 
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